Skip to main content
Medtronic, Aetna enter outcomes-based agreement for insulin pumps

Medtronic and health insurer Aetna have agreed to use clinical outcomes as the basis of payment for Medtronic's insulin pump systems, but financial details of the agreement were not disclosed. The deal will initially concentrate on measuring A1C targets of diabetes patients who use the pumps and may assess hypoglycemia episodes, patient satisfaction, time in proper glycemic range and other measures in the future, said Suzanne Winter, vice president of the Medtronic diabetes group in the Americas.

Full Story: